Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 6:46 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 5,845 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Saline (sodium chloride) Clear all
Not yet recruiting Phase 2 Interventional

Evaluating Intranasal Oxytocin (TNX-1900) for Pain Relief and Recovery After Pituitary Surgery

NCT07730294
View directory record Official record
Conditions
Pain, Pituitary Surgery
Interventions
Oxytocin (Low dose), Oxytocin (High dose), Placebo (saline)
Drug
Lead sponsor
Yale University
Other
Eligibility
30 Years to 75 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 6, 2026, 6:46 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effects of Glucagon Administration on Energy Expenditure

NCT02237053
View directory record Official record
Conditions
Hyperglucagonemia, Obesity
Interventions
Glucagon, Octreotide, Placebo, Insulin
Drug · Behavioral
Lead sponsor
AdventHealth Translational Research Institute
Other
Eligibility
18 Years to 50 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Apr 26, 2018 · Synced Oct 6, 2026, 6:46 AM EDT
Completed Phase 2 Interventional Results available

Trial of IMO-8400 in Adult Patients With Dermatomyositis

NCT02612857
View directory record Official record
Conditions
Dermatomyositis
Interventions
IMO-8400 Dose Group 1, IMO-8400 Dose Group 2, Placebo
Drug
Lead sponsor
Idera Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
17
States / cities
Birmingham, Alabama • Phoenix, Arizona • Irvine, California + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2019 · Synced Oct 6, 2026, 6:46 AM EDT
Completed Phase 2 Interventional

Evaluating New Formulation of Therapeutic HSV-2 Vaccine

NCT02515175
View directory record Official record
Conditions
Genital Herpes Simplex Type 2
Interventions
Matrix-M2, GEN-003, Placebo
Biological · Drug
Lead sponsor
Genocea Biosciences, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
8
States / cities
Birmingham, Alabama • San Diego, California • San Francisco, California + 5 more
Source: ClinicalTrials.gov public record
Updated May 22, 2018 · Synced Oct 6, 2026, 6:46 AM EDT
Terminated Phase 2 Interventional

Study of ST266 in Diabetic Subjects With Deep Burns Managed With Skin Grafts

NCT01715012
View directory record Official record
Conditions
Third Degree Burns, Diabetes
Interventions
ST266, Saline
Biological · Drug
Lead sponsor
Noveome Biotherapeutics, formerly Stemnion
Industry
Eligibility
18 Years to 75 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 15, 2019 · Synced Oct 6, 2026, 6:46 AM EDT
Completed Phase 1 Interventional

Measuring Parkinson's Disease Progression

NCT03205956
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Levodopa
Drug
Lead sponsor
Kevin J. Black, MD
Other
Eligibility
40 Years to 79 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 14, 2022 · Synced Oct 6, 2026, 6:46 AM EDT
Terminated Phase 4 Interventional Results available

Double-Blind Placebo-Controlled CIN Trial

NCT02467075
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
Iopamidol 300 (Contrast), Placebo (Normal Saline)
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 27, 2017 · Synced Oct 6, 2026, 6:46 AM EDT
Completed Phase 3 Interventional Results available

Investigation of PicoPrep Versus HalfLytely for Bowel Preparation for Colonoscopy - Split Dose PicoPrep

NCT01073930
View directory record Official record
Conditions
Bowel Preparation
Interventions
PicoPrep, HalfLytely, bisacodyl
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
608 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
9
States / cities
Huntsville, Alabama • Sherwood, Arkansas • Bristol, Connecticut + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2013 · Synced Oct 6, 2026, 6:46 AM EDT
Not listed Not applicable Interventional

The Impact of Daily Sinus Irrigation on Nasal Symptoms in Continuous Positive Airway Pressure (CPAP) Users - A Pilot Study

NCT01121445
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
NeilMed nose and sinus irrigation
Device
Lead sponsor
Bridgeport Hospital
Other
Eligibility
18 Years to 90 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Bridgeport, Connecticut
Source: ClinicalTrials.gov public record
Updated May 12, 2010 · Synced Oct 6, 2026, 6:46 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

A Study to Evaluate A Range of Dose Levels of Ad26.ZEBOV and MVA-BN-Filo in Healthy Adult Participants

NCT02543567
View directory record Official record
Conditions
Healthy
Interventions
Ad26.ZEBOV 5*10^10 viral particles (vp), Ad26.ZEBOV 2*10^10 (vp), Ad26.ZEBOV 0.8*10^10 (vp), MVA-BN-Filo 1*10^8 Infectious Unit [Inf. U.], MVA-BN-Filo 5*10^7 Inf. U., Placebo
Biological
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
18 Years to 50 Years
Enrollment
525 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
6
States / cities
Huntsville, Alabama • San Diego, California • Melbourne, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated May 25, 2025 · Synced Oct 6, 2026, 6:46 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Pilot Study: Rectus Sheath Blocks for Improving Abdominal Surgery Conditions

NCT02447965
View directory record Official record
Conditions
Hernia, Pain, Postoperative, Abdominal Wall Relaxation After Rectus Sheath Block
Interventions
Bupivacaine, Normal Saline
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jul 21, 2017 · Synced Oct 6, 2026, 6:46 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Drug Interactions Between Morphine and Orally or IV Administered Acetaminophen

NCT02848729
View directory record Official record
Conditions
Pain
Interventions
Oral Acetaminophen, IV Acetaminophen, IV Morphine, Placebo Tablets, Saline
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years to 55 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
3
States / cities
Tucson, Arizona • Naples, Florida • Kingston, Rhode Island
Source: ClinicalTrials.gov public record
Updated Feb 5, 2020 · Synced Oct 6, 2026, 6:46 AM EDT
Withdrawn Not applicable Interventional

Mediastinal Temperature and Post-operative Bleeding

NCT04933253
View directory record Official record
Conditions
Blood Loss, Surgical
Interventions
Saline irrigation
Procedure
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 28, 2022 · Synced Oct 6, 2026, 6:46 AM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

Study of Safety and Efficacy of ALT-100mAb in Participants With Moderate/Severe ARDS

NCT05938036
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome (ARDS)
Interventions
ALT-100 mAb, ALT-100 (Placebo)
Drug
Lead sponsor
Aqualung Therapeutics Corp.
Industry
Eligibility
18 Years to 100 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 23, 2025 · Synced Oct 6, 2026, 6:46 AM EDT
Completed Phase 3 Interventional Results available

Effect of NOV03 on Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction (Mojave Study)

NCT04567329
View directory record Official record
Conditions
Dry Eye Disease
Interventions
NOV03, Saline Solution
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
620 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
35
States / cities
Phoenix, Arizona • Garden Grove, California • Hemet, California + 29 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2024 · Synced Oct 6, 2026, 6:46 AM EDT
Completed Phase 1 Interventional

Study to Investigate Safety, Tolerability, PK and PD Response of SLN360 in Subjects With Elevated Lipoprotein(a)

NCT04606602
View directory record Official record
Conditions
Hyperlipidemias, Dyslipidemias, Elevated Lp(a)
Interventions
SLN360, Placebo
Drug
Lead sponsor
Silence Therapeutics plc
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
4
States / cities
Jacksonville, Florida • Port Orange, Florida • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2024 · Synced Oct 6, 2026, 6:46 AM EDT
Terminated Phase 2 Interventional

Ketamine for OUD and Suicidal Ideation in the ED

NCT06111339
View directory record Official record
Conditions
Opioid Use Disorder, Suicidal Ideation
Interventions
Ketamine, Saline Solution
Drug · Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 8, 2025 · Synced Oct 6, 2026, 6:46 AM EDT
Completed Phase 2 Interventional Results available

Clinical Trial for Parkinson's Disease Using Allogeneic HB-adMSCs (Early and Moderate PD)

NCT04995081
View directory record Official record
Conditions
Parkinson Disease
Interventions
Biological/Vaccine: Allogeneic HB-adMSCs, Placebo
Biological · Other
Lead sponsor
Hope Biosciences Research Foundation
Industry
Eligibility
45 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Sugar Land, Texas
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Oct 6, 2026, 6:46 AM EDT
Completed Early Phase 1 Interventional

Pilot Synovial Fluid Molecular/Stem Cell Response to PRP in Knee Osteoarthritis: Clinical & Imaging Outcome Correlation

NCT02468492
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
Platelet Rich Plasma, Normal Saline
Biological · Other
Lead sponsor
Hunter Holmes Mcguire Veteran Affairs Medical Center
Federal
Eligibility
40 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 16, 2017 · Synced Oct 6, 2026, 6:46 AM EDT
Terminated Phase 2 Interventional Results available

Study of Intravenous Ampion in Adult COVID-19 Patients Requiring Supplemental Oxygen

NCT04839965
View directory record Official record
Conditions
COVID-19
Interventions
Ampion, Saline
Biological · Other
Lead sponsor
Ampio Pharmaceuticals. Inc.
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Englewood, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 30, 2022 · Synced Oct 6, 2026, 6:46 AM EDT
Not listed Phase 1 Interventional

Assessing Ketorolac (Toradol) at Oocyte Retrieval

NCT06026553
View directory record Official record
Conditions
Infertility, Infertility, Female, Oocyte Retrieval, Postoperative Pain, Embryo Transfer
Interventions
Ketorolac (Toradol), Placebo (saline)
Drug · Other
Lead sponsor
Shady Grove Fertility Reproductive Science Center
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
2
States / cities
Rockville, Maryland • Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 7, 2023 · Synced Oct 6, 2026, 6:46 AM EDT
Terminated Phase 1 Interventional Results available

Combination Therapy With VRC01 and 10-1074 in HIV-Infected Individuals Undergoing Sequential Treatment Interruptions

NCT03831945
View directory record Official record
Conditions
HIV
Interventions
VRC-HIVMAB060-00-AB (VRC01), 10-1074, Normal Saline Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 12, 2021 · Synced Oct 6, 2026, 6:46 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

The Effect of Prefrontal Cortex Stimulation on Antisocial and Aggressive Behavior

NCT02427672
View directory record Official record
Conditions
Antisocial Behavior, Aggression
Interventions
Transcranial direct current stimulation, Sham transcranial direct current stimulation
Device
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Oct 6, 2026, 6:46 AM EDT
Completed Not applicable Interventional

Adductor Canal Blocks With Bupivacaine and Magnesium After Same-day Discharge Total Knee Arthroplasty Improve Post-operative Pain Relief and Decrease Opioid Consumption: a Prospective Randomized Controlled Trial

NCT05004636
View directory record Official record
Conditions
Post-operative Pain, Acute
Interventions
Adding Magnesium as an adjuvant to the adductor canal Block (ACB) for same-day discharge total knee arthroplasty
Drug
Lead sponsor
Wayne State University
Other
Eligibility
18 Years to 100 Years
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Pontiac, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 13, 2021 · Synced Oct 6, 2026, 6:46 AM EDT